Semaglutide: 1 Year Impact on Diabetes, Kidney & Heart Health

A year after its approval for use in patients with chronic kidney disease (CKD), semaglutide is demonstrating a transformative impact on the care of individuals with type 2 diabetes, CKD, and related cardiovascular conditions. The drug, initially developed for diabetes management, has shown benefits extending beyond glycemic control, offering potential protection against kidney failure, cardiovascular events, and even death.

Semaglutide’s Mechanism and Initial Approval

Semaglutide belongs to a class of therapeutics known as glucagon-like peptide-1 (GLP-1) receptor agonists. These medications work by mimicking the effects of the naturally occurring GLP-1 hormone, which plays a role in regulating blood sugar, appetite, and insulin secretion. A review published in February 2025 in Arch Intern Med Res details the mechanism of action and formulation of semaglutide therapy, as well as potential benefits and adverse effects.

While initially approved for type 2 diabetes, semaglutide received expanded approval for use in patients with CKD in February 2025. This approval was based on mounting evidence suggesting its protective effects on kidney function and cardiovascular health in this vulnerable population. Patients with type 2 diabetes and CKD face a significantly elevated risk of kidney failure, cardiovascular events, and premature mortality.

FLOW Study Results: A Landmark Trial

The landmark FLOW (Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease) trial provided pivotal evidence supporting semaglutide’s benefits in this patient group. The study, involving over 3,500 participants with type 2 diabetes and CKD, demonstrated a 24% lower risk of a primary-outcome event in those receiving semaglutide compared to placebo. The primary outcome was defined as a composite of kidney failure, a significant reduction in kidney function, or death from kidney-related or cardiovascular causes.

Specifically, the study, detailed in the New England Journal of Medicine, found that semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes. Participants were randomized to receive either subcutaneous semaglutide 1.0 mg weekly or a placebo. After a median follow-up of 3.4 years, the hazard ratio for the primary outcome was 0.76 (95% confidence interval, 0.66 to 0.88; P = 0.0003). This indicates a statistically significant reduction in the risk of adverse events with semaglutide.

Beyond Kidney Protection: Cardiovascular Benefits

The benefits of semaglutide extend beyond kidney protection. The FLOW trial also demonstrated a reduction in the risk of cardiovascular death, with a hazard ratio of 0.71 (95% CI, 0.56 to 0.89). This finding is particularly significant given the high cardiovascular risk associated with both type 2 diabetes and CKD. Research published in the Journal of the American College of Cardiology further supports the positive impact of semaglutide on heart failure outcomes in patients with diabetes and CKD.

Implications for Clinical Practice

The findings from the FLOW trial and other studies are prompting a shift in clinical practice. Semaglutide is increasingly being considered as a first-line therapy for patients with type 2 diabetes and CKD, even in the absence of established cardiovascular disease. The drug’s ability to simultaneously address glycemic control, kidney function, and cardiovascular risk makes it a valuable tool for comprehensive patient management.

The impact is already being felt, with experts noting a transformation in diabetes, kidney, and heart care since the CKD approval. The observed benefits are not limited to slowing the progression of kidney disease; semaglutide also appears to offer a protective effect against major cardiovascular events.

Important Considerations and Future Research

While semaglutide offers significant promise, it’s crucial to acknowledge potential limitations and ongoing areas of research. As with any medication, semaglutide is associated with potential side effects, which are detailed in the Arch Intern Med Res review. Further research is needed to fully understand the long-term effects of semaglutide and to identify which patients are most likely to benefit from this therapy.

The ongoing evolution of understanding surrounding semaglutide underscores the importance of continued investigation and careful clinical monitoring. The initial results, however, are undeniably encouraging, offering a new avenue for improving the health and well-being of individuals living with type 2 diabetes and chronic kidney disease.